Related stories

A new approach to depression

Tue, 08 Oct 2013 16:05:00 +1100

By Deakin Research Communicationsryan.raybould@deakin.edu.au

THE AIM
We would like to study the benefits of adding a new treatment for depression to your usual treatment.

THE REASON
It is believed that the symptoms of depression may be partially caused by increased levels of inflammation and oxidative stress (an imbalance in the levels of antioxidants) in the brain. Minocycline also stimulates the growth and survival of brain cells. There is evidence to suggest that minocycline, a commonly prescribed antibiotic, may have properties that target these factors. Minocycline may be beneficial by reducing inflammation and oxidative stress and stimulating brain cell growth, which may in turn reduce the symptoms experienced by those with depression.
PERSONS ELIGIBLE FOR THE TRIAL
Anyone who is currently experiencing symptoms of depression.
KEY POINTS FOR PARTICIPANTS

The trial will NOT involve any costs.

People will continue their usual treatment.

The treatment trial will last 3 months.

We will meet with you at least 7 times over the course of the trial.

The study is located in Melbourne and Geelong

THE RESEARCHERS
This trial is a joint venture between Deakin University and Barwon Health.

CONTACT DETAILS
Persons wishing to take part in the trial can obtain more information from the trial coordinator:

Dr Olivia Dean
Telephone (03) 4215 3300
mino@barwonhealth.org.au

Dr Olivia Dean

Showcase facts

We would like to study the benefits of adding a new treatment for depression to your usual treatment.